SPACs increasingly are being used to take private biotech and health-care companies public, but they raise special due diligence issues because the companies are highly regulated and their products affect patients, Bloomberg reports, citing Reed Smith attorneys. They outline several key aspects that need extra scrutiny.
Due diligence for biotechnology companies is critical because they tend to be highly regulated by multiple government agencies, and the products can directly affect patients’ health and well-being. Without proper due diligence, latent problems could cause issues at any moment, putting the company and its investors’ funds at risk. Read more.
Related Posts
Forbes: How are SPACs Affecting the Media Industry?
The vehicle has been a specific target of entities in the media industry but there seems to still be caution around its viability.
UK to Boost ‘Dormant’ Market for SPACs: Report
The UK intends to overhaul stock exchange rules around blank-check companies as part of wide-ranging reforms to boost the attractiveness of London after Brexit, BusinessDay reports.
Trump-Tied SPAC Files 8-K with a Few More Details
Still no information on TMTG management or even the most rudimentary outline of its business plans, services to be offered or prospects of becoming profitable.
Malaysian Aviation Group Capital A Mulls Potential SPAC Deal to Get on a US Exchange
Capital A, formerly known as AirAsia Group Berhad, was hard-hit by pandemic travel restrictions in Asia, leading Bursa Malaysia Securities to classify it as a PN17 company, or financially distressed.